Application of nanotechnologies for improved immune response against infectious diseases in the developing world

M Look, A Bandyopadhyay, JS Blum… - Advanced drug delivery …, 2010 - Elsevier
There is an urgent need for new strategies to combat infectious diseases in developing
countries. Many pathogens have evolved to elude immunity and this has limited the utility of …

Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies

R Klippstein, D Pozo - Nanomedicine: Nanotechnology, Biology and …, 2010 - Elsevier
Dendritic cells (DCs) are potent antigen-presenting cells capable of initiating a primary
immune response and possess the ability to activate T cells and stimulate the growth and …

Invariant natural killer T cell-based therapy of autoimmune diseases

CL Gabriel, L Wu, VV Parekh… - Current Immunology …, 2010 - ingentaconnect.com
Invariant natural killer T (iNKT) cells are a unique subset of T lymphocytes that share
characteristics with both innate and adaptive immune cells. The iNKT cell receptor …

Assessment of mycolic acids as ligand for nanoencapsulated anti-tuberculosis drug targeting

Y Lemmer - 2010 - repository.up.ac.za
South Africa currently has the highest incidence of TB per 100 000 people in the world. In
2007 alone 112 000 people died of TB in South Africa, of which 94 000 were co-infected …

Characterization of alpha-galactosylceramide as a mucosal adjuvant

AN Courtney - 2010 - digitalcommons.library.tmc.edu
Adjuvants are essential components of vaccine formulations that enhance adaptive immune
responses to antigens, particularly for immunizations targeting the tolerogenic mucosal …